These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

429 related items for PubMed ID: 8855293

  • 1. Vaccination with syngeneic, lymphoma-derived immunoglobulin idiotype combined with granulocyte/macrophage colony-stimulating factor primes mice for a protective T-cell response.
    Kwak LW, Young HA, Pennington RW, Weeks SD.
    Proc Natl Acad Sci U S A; 1996 Oct 01; 93(20):10972-7. PubMed ID: 8855293
    [Abstract] [Full Text] [Related]

  • 2. Linkage of foreign carrier protein to a self-tumor antigen enhances the immunogenicity of a pulsed dendritic cell vaccine.
    Timmerman JM, Levy R.
    J Immunol; 2000 May 01; 164(9):4797-803. PubMed ID: 10779787
    [Abstract] [Full Text] [Related]

  • 3. Immunostimulatory CpG oligodeoxynucleotides enhance the immune response to vaccine strategies involving granulocyte-macrophage colony-stimulating factor.
    Liu HM, Newbrough SE, Bhatia SK, Dahle CE, Krieg AM, Weiner GJ.
    Blood; 1998 Nov 15; 92(10):3730-6. PubMed ID: 9808567
    [Abstract] [Full Text] [Related]

  • 4. Conjugation of lymphoma idiotype to CD40 antibody enhances lymphoma vaccine immunogenicity and antitumor effects in mice.
    Carlring J, Szabo MJ, Dickinson R, De Leenheer E, Heath AW.
    Blood; 2012 Mar 01; 119(9):2056-65. PubMed ID: 22234700
    [Abstract] [Full Text] [Related]

  • 5. Sulfhydryl-based tumor antigen-carrier protein conjugates stimulate superior antitumor immunity against B cell lymphomas.
    Betting DJ, Kafi K, Abdollahi-Fard A, Hurvitz SA, Timmerman JM.
    J Immunol; 2008 Sep 15; 181(6):4131-40. PubMed ID: 18768870
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Listeriolysin O is an improved protein carrier for lymphoma immunoglobulin idiotype and provides systemic protection against 38C13 lymphoma.
    Neeson P, Pan ZK, Paterson Y.
    Cancer Immunol Immunother; 2008 Apr 15; 57(4):493-505. PubMed ID: 17876582
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Immunogenicity of a plasmid DNA vaccine encoding chimeric idiotype in patients with B-cell lymphoma.
    Timmerman JM, Singh G, Hermanson G, Hobart P, Czerwinski DK, Taidi B, Rajapaksa R, Caspar CB, Van Beckhoven A, Levy R.
    Cancer Res; 2002 Oct 15; 62(20):5845-52. PubMed ID: 12384547
    [Abstract] [Full Text] [Related]

  • 10. Idiotype vaccination against murine B cell lymphoma. Humoral and cellular requirements for the full expression of antitumor immunity.
    Campbell MJ, Esserman L, Byars NE, Allison AC, Levy R.
    J Immunol; 1990 Aug 01; 145(3):1029-36. PubMed ID: 2373859
    [Abstract] [Full Text] [Related]

  • 11. Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients.
    Timmerman JM, Czerwinski DK, Davis TA, Hsu FJ, Benike C, Hao ZM, Taidi B, Rajapaksa R, Caspar CB, Okada CY, van Beckhoven A, Liles TM, Engleman EG, Levy R.
    Blood; 2002 Mar 01; 99(5):1517-26. PubMed ID: 11861263
    [Abstract] [Full Text] [Related]

  • 12. Immunization with granulocyte-macrophage colony-stimulating factor-transduced, but not B7-1-transduced, lymphoma cells primes idiotype-specific T cells and generates potent systemic antitumor immunity.
    Levitsky HI, Montgomery J, Ahmadzadeh M, Staveley-O'Carroll K, Guarnieri F, Longo DL, Kwak LW.
    J Immunol; 1996 May 15; 156(10):3858-65. PubMed ID: 8621924
    [Abstract] [Full Text] [Related]

  • 13. Long-term follow-up of idiotype vaccination in human myeloma as a maintenance therapy after high-dose chemotherapy.
    Coscia M, Mariani S, Battaglio S, Di Bello C, Fiore F, Foglietta M, Pileri A, Boccadoro M, Massaia M.
    Leukemia; 2004 Jan 15; 18(1):139-45. PubMed ID: 14574332
    [Abstract] [Full Text] [Related]

  • 14. Granulocyte-macrophage colony-stimulating factor: an effective adjuvant for protein and peptide-based vaccines.
    Disis ML, Bernhard H, Shiota FM, Hand SL, Gralow JR, Huseby ES, Gillis S, Cheever MA.
    Blood; 1996 Jul 01; 88(1):202-10. PubMed ID: 8704175
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. A genetic approach to idiotypic vaccination for B cell lymphoma.
    Stevenson FK, Zhu D, King CA, Ashworth LJ, Kumar S, Thompsett A, Hawkins RE.
    Ann N Y Acad Sci; 1995 Nov 27; 772():212-26. PubMed ID: 8546396
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Tumor cell lysate-pulsed dendritic cells are more effective than TCR Id protein vaccines for active immunotherapy of T cell lymphoma.
    Gatza E, Okada CY.
    J Immunol; 2002 Nov 01; 169(9):5227-35. PubMed ID: 12391241
    [Abstract] [Full Text] [Related]

  • 19. A nine-amino acid peptide from IL-1beta augments antitumor immune responses induced by protein and DNA vaccines.
    Hakim I, Levy S, Levy R.
    J Immunol; 1996 Dec 15; 157(12):5503-11. PubMed ID: 8955200
    [Abstract] [Full Text] [Related]

  • 20. The targeting of CD4+ T lymphocytes to a B cell lymphoma. A comparison of anti-CD3-anti-idiotype antibody conjugates and antigen-anti-idiotype antibody conjugates.
    Gravelle M, Ochi A.
    J Immunol; 1989 Jun 01; 142(11):4079-84. PubMed ID: 2523940
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.